New combo therapy aims to shrink enlarged spleens in bone marrow cancer patients
Disease control
Not yet recruiting
This study tests whether adding bomedemstat to the standard drug momelotinib can help people with myelofibrosis, a type of bone marrow cancer. It is for patients whose spleen is still enlarged after 12 weeks on momelotinib alone. The main goal is to see if the combination reduces…
Phase: PHASE2 • Sponsor: United Lincolnshire Hospitals NHS Trust • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC